The clinical trial, which started to enroll patients in January 2011, is being conducted under an FDA-approved special protocol assessment, says Galena President and CEO Mark Ahn.
FORBES: Roche Accelerates Defense Strategy to Protect Breast-Cancer Drug Herceptin's Turf